Theriva Biologics Gains Orphan Drug Status for VCN-01

Theriva Biologics ( (TOVX) ) has issued an update.

Theriva Biologics has announced that the European Commission granted orphan medicinal product designation to its leading candidate VCN-01 for treating retinoblastoma, highlighting the urgent need for new therapies. This designation, following similar recognition by the FDA, underscores VCN-01’s potential to transform treatment options, offering significant benefits to patients by enhancing chemotherapy effectiveness and improving immune response against tumors.

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.